The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Induction of myelodysplasia by myeloid-derived suppressor cells
Open accessAbstract
Myelodysplastic syndromes (MDS) are age-dependent stem cell malignancies that share biological features of activated adaptive immune response and ineffective hematopoiesis. Here we report that myeloid-derived suppressor cells (MDSC), which are classically linked to immunosuppression, inflammation, and cancer, were markedly expanded in the bone marrow of MDS patients and played a pathogenetic role in the development of ineffective hematopoiesis. These clonally distinct MDSC overproduce hematopoietic suppressive cytokines and function as potent apoptotic effectors targeting autologous hematopoietic progenitors. Using multiple transfected cell models, we found that MDSC expansion is driven by the interaction of the proinflammatory molecule S100A9 with CD33. These 2 proteins formed a functional ligand/receptor pair that recruited components to CD33’s immunoreceptor tyrosine-based inhibition motif (ITIM), inducing secretion of the suppressive cytokines IL-10 and TGF-β by immature myeloid cells. S100A9 transgenic mice displayed bone marrow accumulation of MDSC accompanied by development of progressive multilineage cytopenias and cytological dysplasia. Importantly, early forced maturation of MDSC by either all-trans-retinoic acid treatment or active immunoreceptor tyrosine-based activation motif–bearing (ITAM-bearing) adapter protein (DAP12) interruption of CD33 signaling rescued the hematologic phenotype. These findings indicate that primary bone marrow expansion of MDSC driven by the S100A9/CD33 pathway perturbs hematopoiesis and contributes to the development of MDS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MDSCs are sufficient to create an MDS phenotype in murine experiments, and targeting them or their expansion leads to reconstitution of normal hematopoiesis.76,77”
From Inflammatory bone marrow microenvironment (2019) · cites this paper as [76]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Self-citationLanier, L. L. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115526 · Cited by 2,765
Siglecs and their roles in the immune system
Crocker, P. R., Paulson, J. C., & Varki, A. P. (2007) · Nature reviews. Immunology · doi:10.1038/nri2056 · Cited by 2,032
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand‐Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,777
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J., Nagaraj, S., Collazo, M. M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Self-citationVogl, T., Tenbrock, K., Ludwig, S., Leukert, N., Ehrhardt, C., van Zoelen, M. A. D., Nacken, W., Foell, D., van der Poll, T., Sorg, C., et al. (2007) · Nature Medicine · doi:10.1038/nm1638 · Cited by 1,418 · cited 2×
“Given our findings that S100A9 triggers CD33/Siglec 3 signaling and is involved in MDSC activation (17, 18, 37), we generated S100A9Tg mice to study MDSC-associated inflammation (37).”
Ravetch, J. V., & Lanier, L. L. (2000) · Science · doi:10.1126/science.290.5489.84 · Cited by 1,278
Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia
Raaijmakers, M. H. G. P., Mukherjee, S., Guo, S., Zhang, S., Kobayashi, T., Schoonmaker, J. A., Ebert, B. L., Al-Shahrour, F., Hasserjian, R. P., Scadden, E. O., et al. (2010) · Nature · doi:10.1038/nature08851 · Cited by 1,115
Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells
Lanier, L. L., Corliss, B. C., Wu, J., Leong, C. C., & Phillips, J. H. (1998) · Nature · doi:10.1038/35642 · Cited by 907
Cheng, P., Corzo, C. A., Luetteke, N., Yu, B., Nagaraj, S., Bui, M. M., Ortiz, M. L., Nacken, W. K. F., Sorg, C., Vogl, T., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080132 · Cited by 904
Self-citation
Flagged first, then by citations
Research works printed but not linked: 3
- Kapanadze, 2013, J Hepatol., pii, S0168-8278(13)00421-2
- Xu, 2010, J Biomed Biotechnol., 2010, 105940
- Ioachim HL Medeiros LJ Cytopathology. In: Iochim’s Lymph Node Pathology. 4th ed. Philadelphia, Pennsylvania, USA: Wolters Kluwer/Lippincott Williams &Wilkins; 2008 21 22
Cited by
Sorted by citations
Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19
Silvin, A., Chapuis, N., Dunsmore, G., Goubet, A.-G., Dubuisson, A., Derosa, L., Almire, C., Hénon, C., Kosmider, O., Droin, N., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.002 · Cited by 834
Calprotectin: from biomarker to biological function
Jukic, A., Bakiri, L., Wagner, E. F., Tilg, H., & Adolph, T. E. (2021) · Gut · doi:10.1136/gutjnl-2021-324855 · Cited by 500
Myeloid-derived suppressor cells in cancer and cancer therapy
Lasser, S., Kurt, F. G. Ö., Arkhypov, I., Utikal, J. S., & Umansky, V. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00846-y · Cited by 523
Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
Wu, Y., Yi, M., Niu, M., Mei, Q., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01657-y · Cited by 475
The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype
Basiorka, A. A., McGraw, K. L., Eksioglu, E. A., Chen, X., Johnson, J., Zhang, L., Zhang, Q., Irvine, B. A., Cluzeau, T., Sallman, D. A., et al. (2016) · Blood · doi:10.1182/blood-2016-07-730556 · Cited by 367
Self-citationZambetti, N. A., Ping, Z., Chen, S., Kenswil, K. J. G., Mylona, M. A., Sanders, M. A., Hoogenboezem, R. M., Bindels, E. M. J., Adisty, M. N., Van Strien, P. M. H., et al. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.08.021 · Cited by 342
Inflammation-Induced Tumorigenesis and Metastasis
Hibino, S., Kawazoe, T., Kasahara, H., Itoh, S., Ishimoto, T., Sakata‐Yanagimoto, M., & Taniguchi, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115421 · Cited by 319
The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes
Sallman, D. A., & List, A. (2019) · Blood · doi:10.1182/blood-2018-10-844654 · Cited by 273
Self-citationGleason, M., Ross, J. A., Warlick, E. D., Lund, T. C., Verneris, M. R., Wiernik, A., Spellman, S. R., Haagenson, M. D., Lenvik, A. J., Litzow, M. R., et al. (2014) · Blood · doi:10.1182/blood-2013-10-533398 · Cited by 266
Self-citationRps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9
Schneider, R. K., Schenone, M., Ferreira, M. S. V., Kramann, R., Joyce, C. E., Hartigan, C. R., Beier, F., Brümmendorf, T. H., Germing, U., Platzbecker, U., et al. (2016) · Nature Medicine · doi:10.1038/nm.4047 · Cited by 246
Hypersialylation in Cancer: Modulation of Inflammation and Therapeutic Opportunities
Rodrigues, E., & Macauley, M. S. (2018) · Cancers · doi:10.3390/cancers10060207 · Cited by 238
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
Gañán-Gómez, I., Wei, Y., Starczynowski, D. T., Colla, S., Yang, H., Cabrero-Calvo, M., Bohannan, Z. S., Verma, A., Steidl, U., & Garcia-Manero, G. (2015) · Leukemia · doi:10.1038/leu.2015.69 · Cited by 236
Chronic immune response dysregulation in MDS pathogenesis
Barreyro, L., Chlon, T. M., & Starczynowski, D. T. (2018) · Blood · doi:10.1182/blood-2018-03-784116 · Cited by 226
Phenotype, development, and biological function of myeloid-derived suppressor cells
Zhao, Y., Wu, T., Shao, S., Shi, B., & Zhao, Y. X. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1004983 · Cited by 220
Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment
van de Wall, S., Santegoets, K. C. M., van Houtum, E. J. H., Büll, C., & Adema, G. J. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.02.001 · Cited by 211
Sarhan, D., Cichocki, F. M., Zhang, B., Yingst, A. M., Spellman, S. R., Cooley, S., Verneris, M. R., Blazar, B. R., & Miller, J. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0839 · Cited by 198
COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects
Smadja, D. M., Mentzer, S. J., Fontenay, M., Laffan, M., Ackermann, M., Helms, J., Jonigk, D. D., Chocron, R., Pier, G. B., Gendron, N., et al. (2021) · Angiogenesis · doi:10.1007/s10456-021-09805-6 · Cited by 204
MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia
Pyzer, A. R., Stroopinsky, D., Rajabi, H. N., Washington, A. J., Tagde, A., Coll, M. D., Fung, J., Bryant, M. P., Cole, L., Palmer, K. A., et al. (2017) · Blood · doi:10.1182/blood-2016-07-730614 · Cited by 199
Daver, N. G., Boddu, P. C., Garcia‐Manero, G., Yadav, S. S., Sharma, P., Allison, J. P., & Kantarjian, H. M. (2018) · Leukemia · doi:10.1038/s41375-018-0070-8 · Cited by 183
IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells
Schinke, C., Giricz, O., Li, W., Shastri, A., Gordon, S. A. K., Barreyro, L., Bhagat, T. D., Bhattacharyya, S., Ramachandra, N., Bartenstein, M., et al. (2015) · Blood · doi:10.1182/blood-2015-01-621631 · Cited by 183
Genetics of progression from MDS to secondary leukemia
Menssen, A. J., & Walter, M. J. (2020) · Blood · doi:10.1182/blood.2019000942 · Cited by 182
Sweet escape: Sialic acids in tumor immune evasion
Büll, C., den Brok, M. H., & Adema, G. J. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.07.005 · Cited by 158
The bone-marrow niche in MDS and MGUS: implications for AML and MM
Ghobrial, I. M., Detappe, A., Anderson, K. C., & Steensma, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.197 · Cited by 156
S100A9 induces differentiation of acute myeloid leukemia cells through TLR4
Laouedj, M., Tardif, M. R., Gil, L., Raquil, M.-A., Lachhab, A., Pelletier, M., Tessier, P. A., & Barabé, F. (2017) · Blood · doi:10.1182/blood-2016-09-738005 · Cited by 142
Dynamic responses of the haematopoietic stem cell niche to diverse stresses
Batsivari, A., Haltalli, M. L. R., Passaro, D., Pospori, C., Celso, C. L., & Bonnet, D. A. (2020) · Nature Cell Biology · doi:10.1038/s41556-019-0444-9 · Cited by 139
Autoimmune diseases and myelodysplastic syndromes
Komrokji, R. S., Kulasekararaj, A. G., Ali, N. H. A., Kordasti, S. Y., Bart‐Smith, E., Craig, B. M., Padron, E., Zhang, L., Lancet, J. E., Pinilla-Ibarz, J. A., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24333 · Cited by 133
Self-citationKittang, A. O., Kordasti, S. Y., Sand, K. E., Costantini, B., Kramer, A. M., Abellan, P. P., Seidl, T., Rye, K. P., Hagen, K. M., Kulasekararaj, A. G., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1062208 · Cited by 132
The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma
Ou, A. C., Ott, M., Fang, D., & Heimberger, A. B. (2021) · Cancers · doi:10.3390/cancers13030437 · Cited by 132
The microenvironment in human myeloid malignancies: emerging concepts and therapeutic implications
Medyouf, H. (2017) · Blood · doi:10.1182/blood-2016-11-696070 · Cited by 133
STAT3 in Tumor-Associated Myeloid Cells: Multitasking to Disrupt Immunity
Su, Y., Banerjee, S., White, S. V., & Kortylewski, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061803 · Cited by 125
Stem and progenitor cell alterations in myelodysplastic syndromes
Shastri, A., Will, B., Steidl, U. G., & Verma, A. K. (2017) · Blood · doi:10.1182/blood-2016-10-696062 · Cited by 123
Myeloid-derived suppressor cells in hematological malignancies: friends or foes
Lv, M., Wang, K., & Huang, X. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0797-3 · Cited by 121
Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype
Sallman, D. A., Cluzeau, T., Basiorka, A. A., & List, A. F. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00151 · Cited by 117
Self-citationRegulation of the Bone Marrow Niche by Inflammation
Mitroulis, I., Kalafati, L., Bornhäuser, M., Hajishengallis, G., & Chavakis, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01540 · Cited by 118
Varney, M. E., Niederkorn, M., Konno, H., Matsumura, T., Gohda, J., Yoshida, N., Akiyama, T., Christie, S., Fang, J., Miller, D., et al. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20141898 · Cited by 111
Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
Liu, Y., Bewersdorf, J. P., Stahl, M. F., & Zeidan, A. M. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.12.001 · Cited by 112
The Role of Toll-Like Receptors in Hematopoietic Malignancies
Monlish, D. A., Bhatt, S. T., & Schuettpelz, L. G. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00390 · Cited by 104
S100A8/A9 in COVID-19 pathogenesis: Impact on clinical outcomes
Mellett, L., & Khader, S. A. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.10.004 · Cited by 105
Cheng, P., Eksioglu, E. A., Chen, X., Kandell, W. M., Trinh, T. L., Cen, L., Qi, J., Sallman, D. A., Zhang, Y., Tu, N., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0397-9 · Cited by 103
Self-citationThe immunology of SARS-CoV-2 infections and vaccines
Grigoryan, L., & Pulendran, B. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101422 · Cited by 102
Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia
Fang, J., Bolanos, L. C., Choi, K., Liu, X., Christie, S., Akunuru, S., Kumar, R., Wang, D., Chen, X., Greis, K. D., et al. (2016) · Nature Immunology · doi:10.1038/ni.3654 · Cited by 100
Self-citationMyeloid‐derived suppressor cells as effectors of immune suppression in cancer
Pyzer, A. R., Cole, L., Rosenblatt, J. M., & Avigan, D. (2016) · International Journal of Cancer · doi:10.1002/ijc.30232 · Cited by 101
IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies
Bennett, J., & Starczynowski, D. T. (2021) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000693 · Cited by 100
Li, Z.-L., Ye, S., OuYang, L.-Y., Zhang, H., Chen, Y.-S., He, J., Chen, Q.-Y., Qian, C.-N., Zhang, X.-S., Cui, J., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1044712 · Cited by 98
Wang, C., Yan, Y., Gao, S., Chen, J., Yu, J., Zhang, H., Li, M., Zhan, X., & Li, W. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.12.013 · Cited by 95
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
Yang, X., Ma, L., Zhang, X., Huang, L., & Wei, J. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00263-4 · Cited by 103
Griffiths, E. A., Srivastava, P., Matsuzaki, J., Brumberger, Z. L., Wang, E. S., Kocent, J., Miller, A., Roloff, G. W., Wong, H. Y., Paluch, B. E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1792 · Cited by 94
Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy
Hao, Z., Li, R., Wang, Y., Li, S., Hong, Z., & Han, Z. (2021) · Biomarker Research · doi:10.1186/s40364-021-00333-5 · Cited by 99
Roussel, M., Ferrell, P. B., Greenplate, A. R., Lhomme, F., Le Gallou, S., Diggins, K. E., Johnson, D. B., & Irish, J. M. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5ma1116-457r · Cited by 93
Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models
Shen, L., Sundstedt, A., Ciesielski, M. J., Miles, K. M., Celander, M., Adelaiye-Ogala, R. M., Orillion, A. R., Ciamporcero, E. S., Ramakrishnan, S., Ellis, L., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0036 · Cited by 96
The Untold Story of Granzymes in Oncoimmunology: Novel Opportunities with Old Acquaintances
Arias, M. A., Martínez‐Lostao, L., Santiago, L., Ferrández, Á., Granville, D. J., & Pardo, J. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.04.001 · Cited by 97
TGF-β signaling networks in the tumor microenvironment
Chan, M. K.-K., Chung, J. Y.-F., Tang, P. C.-T., Chan, A. S.-W., Ho, J. Y.-Y., Lin, T. P.-T., Chen, J., Leung, K.-T., To, K.-F., Lan, H.-Y., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215925 · Cited by 90
Immune escape and resistance to immunotherapy in mismatch repair deficient tumors
Mestrallet, G., Brown, M., Bozkus, C. C., & Bhardwaj, N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1210164 · Cited by 91
Li, J., Shu, X., Xu, J., Su, S. M., Chan, U. I., Mo, L., Liu, J., Zhang, X., Adhav, R., Chen, Q., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29151-5 · Cited by 90
The impact of metal availability on immune function during infection
Monteith, A. J., & Skaar, E. P. (2021) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2021.08.004 · Cited by 83
Winter, S., Shoaie, S., Kordasti, S. Y., & Platzbecker, U. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01823 · Cited by 82
Inflammatory bone marrow microenvironment
Leimkühler, N. B., & Schneider, R. K. (2019) · Hematology · doi:10.1182/hematology.2019000045 · Cited by 82
Ortiz, M. L., Kumar, V., Martner, A., Mony, S., Donthireddy, L., Condamine, T., Seykora, J. T., Knight, S. C., Malietzis, G. A., Lee, G. H., et al. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20140835 · Cited by 82
Self-citationWang, T., Pine, A. R., Kotini, A. G., Yuan, H., Zamparo, L., Starczynowski, D. T., Leslie, C. S., & Papapetrou, E. P. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.01.011 · Cited by 77
Choudhary, G. S., Pellagatti, A., Agianian, B., Smith, M. A., Bhagat, T. D., Gordon-Mitchell, S., Sahu, S., Pandey, S., Shah, N. N., Aluri, S., et al. (2022) · eLife · doi:10.7554/elife.78136 · Cited by 76
The genetic and molecular pathogenesis of myelodysplastic syndromes
Shallis, R. M., Ahmad, R., & Zeidan, A. M. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13092 · Cited by 76
The Engagement Between MDSCs and Metastases: Partners in Crime
Trovato, R., Canè, S., Petrova, V., Sartoris, S., Ugel, S., & Sanctis, F. D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00165 · Cited by 74
Mei, Y., Zhao, B., Basiorka, A. A., Yang, J. C., Cao, L., Zhang, J., List, A. F., & Ji, P. (2017) · Leukemia · doi:10.1038/leu.2017.326 · Cited by 72
Self-citationS100 Proteins in the Innate Immune Response to Pathogens
Kozlyuk, N., Monteith, A. J., Garcia, V., Damo, S. M., Skaar, E. P., & Chazin, W. J. (2019) · Methods in Molecular Biology · doi:10.1007/978-1-4939-9030-6_18 · Cited by 72
The inflammatory microenvironment in MDS
Yang, L., Qian, Y., Eksioglu, E. A., Epling‐Burnette, P. K., & Sheng, W. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1846-x · Cited by 70
Self-citationZhang, L., McGraw, K. L., Sallman, D. A., & List, A. F. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1266625 · Cited by 67
Self-citationEksioglu, E. A., Chen, X., Heider, K.-H., Rueter, B., McGraw, K. L., Basiorka, A. A., Wei, M., Burnette, A., Cheng, P., Lancet, J., et al. (2017) · Leukemia · doi:10.1038/leu.2017.21 · Cited by 66
Self-citationBiological drivers of clinical phenotype in myelofibrosis
Mascarenhas, J. O., Gleitz, H. F. E., Chifotides, H. T., Harrison, C. N., Verstovšek, S., Vannucchi, A. M., Rampal, R. K., Kiladjian, J., Vainchenker, W., Hoffman, R., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01767-y · Cited by 70
Self-citationStress and Non-Stress Roles of Inflammatory Signals during HSC Emergence and Maintenance
Clapes, T., Lefkopoulos, S., & Trompouki, E. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00487 · Cited by 66
Geyh, S., Rodríguez‐Paredes, M., Jäger, P. S., Koch, A., Bormann, F., Gutekunst, J., Zilkens, C., Germing, U., Kobbe, G., Lyko, F., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.186734 · Cited by 65
Immunogenic Cell Death in Hematological Malignancy Therapy
Liu, Z., Xu, X., Liu, K., Zhang, J., Ding, D., & Fu, R. (2023) · Advanced Science · doi:10.1002/advs.202207475 · Cited by 63
The microenvironment in myelodysplastic syndromes: Niche-mediated disease initiation and progression
Li, A. J., & Calvi, L. M. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.08.003 · Cited by 66
Improving cancer immunotherapy by targeting the STATe of MDSCs
de Haas, N., de Koning, C. C. H., Spilgies, L. M., de Vries, I. J. M., & Hato, S. V. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1196312 · Cited by 63
Mondet, J., Chevalier, S., & Mossuz, P. (2021) · Molecules · doi:10.3390/molecules26051323 · Cited by 61
Pleyer, L., Valent, P., & Greil, R. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071009 · Cited by 63
Autoimmunity and Inflammation in Myelodysplastic Syndromes
Wolach, O., & Stone, R. M. (2016) · Acta Haematologica · doi:10.1159/000446062 · Cited by 61
Crucial roles of different RNA-binding hnRNP proteins in Stem Cells
Xie, W. J., Zhu, H., Zhao, M., Wang, L., Li, S., Zhao, C., Zhou, Y., Zhu, B., Jiang, X., Liu, W., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.55120 · Cited by 56
Tohumeken, Ş., Baur, R., Böttcher, M., Stoll, A., Loschinski, R., Panagiotidis, K., Braun, M., Saul, D., Völkl, S., Baur, A. S., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0024 · Cited by 58
Myeloid‐Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets
Bizymi, N., Bjelica, S., Kittang, A. O., Mojsilović, S. B., Velegraki, M., Pontikoglou, C. G., Roussel, M., Ersvær, E., Santibanez, J. F., Lipoldová, M., et al. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000168 · Cited by 58
Chen, B., Song, J., Hu, C.-L., Chen, S.-B., Zhang, Q., Xu, C., Wu, J., Hou, D., Sun, M., Zhang, Y.-L., et al. (2020) · Blood · doi:10.1182/blood.2019001963 · Cited by 53
Garcia, V., Perera, Y. R., & Chazin, W. (2022) · Biomolecules · doi:10.3390/biom12040519 · Cited by 54
CD14 Is a Co-Receptor for TLR4 in the S100A9-Induced Pro-Inflammatory Response in Monocytes
He, Z., Riva, M., Björk, P., Swärd, K., Mörgelin, M., Leanderson, T., & Ivars, F. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156377 · Cited by 51
Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes
Banerjee, T., Calvi, L. M., Becker, M. W., & Liesveld, J. L. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.04.004 · Cited by 53
Paracatu, L. C., & Schuettpelz, L. G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01236 · Cited by 51
Ward, G., Dalton, R., Meyer, B. S., McLemore, A. F., Aldrich, A. L., Lam, N. B., Onimus, A., Vincelette, N. D., Trinh, T. L., Chen, X., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043896 · Cited by 50
Self-citationSarhan, D., Wang, J., Arvindam, U. S., Hallstrom, C., Verneris, M. R., Grzywacz, B. J., Warlick, E. D., Blazar, B. R., & Miller, J. S. (2020) · JCI Insight · doi:10.1172/jci.insight.130155 · Cited by 55
Emerging Canonical and Non-Canonical Roles of Granzyme B in Health and Disease
Tibbs, E. J., & Cao, X. (2022) · Cancers · doi:10.3390/cancers14061436 · Cited by 52
Zhou, T., Kinney, M. C., Scott, L. M., Zinkel, S. S., & Rebel, V. I. (2015) · Blood · doi:10.1182/blood-2015-01-624239 · Cited by 49
Cluzeau, T., McGraw, K. L., Irvine, B. A., Masala, E., Adès, L., Basiorka, A. A., Maciejewski, J. P., Auberger, P., Wei, S., Fenaux, P., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.158857 · Cited by 49
Self-citationExpression profiling of immune inhibitory Siglecs and their ligands in patients with glioma
Santegoets, K. C. M., Gielen, P. R., Büll, C., Schulte, B. M., Kers‐Rebel, E. D., Küsters, B., Bossmann, S. A. J. F. H., ter Laan, M., Wesseling, P., & Adema, G. J. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02332-w · Cited by 48
Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes
Kouroukli, O., Symeonidis, A. S., Foukas, P. G., Maragkou, M., & Kourea, E. P. (2022) · Cancers · doi:10.3390/cancers14225656 · Cited by 52
Heinemann, A. S., Pirr, S. M., Fehlhaber, B., Mellinger, L., Burgmann, J., Busse, M., Ginzel, M., Friesenhagen, J., von Köckritz‐Blickwede, M., Ulas, T., et al. (2016) · The FASEB Journal · doi:10.1096/fj.201601083r · Cited by 47
Stoll, B., Lim, H., & Park, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051468 · Cited by 47
Cheng, P., Chen, X., Dalton, R., Calescibetta, A. R., So, T., Gilvary, D. L., Ward, G., Smith, V., Eckard, S. C., Fox, J. A., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.005 · Cited by 47
Self-citationInflammation and myeloid malignancy: quenching the flame
Stubbins, R. J., Platzbecker, U., & Karsan, A. (2022) · Blood · doi:10.1182/blood.2021015162 · Cited by 46
The inflammatory cytokine profile of myelodysplastic syndromes
Shi, X., Zheng, Y., Xu, L., Cao, C., Dong, B., & Chen, X. (2019) · Medicine · doi:10.1097/md.0000000000015844 · Cited by 46
Self-citationDamiani, D., Tiribelli, M., Raspadori, D., Sirianni, S., Meneghel, A., Cavallin, M., Michelutti, A., Toffoletti, E., Geromin, A., Simeone, E., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4901 · Cited by 45
Mœller, A., Jauch-Speer, S.-L., Gandhi, S., Vogl, T. J., Roth, J., & Fehler, O. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1110185 · Cited by 44
Yu, S., Ren, X., Meng, F., Guo, X., Tao, J., Zhang, W., Liu, Z., Fu, R., & Li, L. (2022) · Immunology · doi:10.1111/imm.13488 · Cited by 43
Self-citationWieboldt, R., Sandholzer, M. T., Carlini, E., Lin, C., Börsch, A., Zingg, A., Lardinois, D., Herzig, P., Don, L., Zippelius, A., et al. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01142-0 · Cited by 43
Metadata
- Authors
- Chen, X., Eksioglu, E. A., Zhou, J., Zhang, L., Djeu, J., Fortenbery, N., Epling-Burnette, P., Van Bijnen, S., Dolstra, H., Cannon, J., Youn, J.-I., Donatelli, S. S., Qin, D., De Witte, T., Tao, J., Wang, H., Cheng, P., Gabrilovich, D. I., List, A., & Wei, S.
- Affiliations
- Moffitt Cancer Center (US)
- Radboud University Medical Center (NL)
- University of South Florida (US)
- Corresponding author
- Wei, Sheng
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2013-10-15
- Volume
- 123
- Issue
- 11
- Pages
- 4595-4611
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3809779
- OpenAlex
- W2111063688
- Cited by
- 316
- References
- 63
- Citations by year
- 2026: 17 · 2025: 18 · 2024: 19 · 2023: 28 · 2022: 31 · 2021: 43 · 2020: 30 · 2019: 26 · 2018: 23 · 2017: 25 · 2016: 30 · 2015: 17 · 2014: 9
- FWCI
- 10.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- National Institutes of Health (AI056213)
- National Cancer Institute (T32CA115308, R01CA131076, R01CA100062, P30CA076292)
- National Institute of Allergy and Infectious Diseases (AI056213, R01AI056213)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- myelodysplastic syndrome, myeloid-derived suppressor cells, ineffective hematopoiesis, S100A9, CD33, immunoreceptor tyrosine-based inhibition motif, ITAM, DAP12, IL-10, TGF-beta, bone marrow, all-trans retinoic acid, transgenic mice
- MeSH terms
- Animals, Disease Models, Animal, Female, Hematopoiesis, HLA-DR Antigens, Humans, Ligands, Male, Mice, Transgenic, Myelodysplastic Syndromes, Signal Transduction, Mice, Knockout, Adoptive Transfer, Myeloid Cells, Calgranulin A, Calgranulin B, Mice, Cellular Microenvironment, Sialic Acid Binding Ig-like Lectin 3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
